Emerging drugs for diabetic peripheral neuropathy and neuropathic pain

References

• Ziegler D, Papanas N, Vinik AI, et al. Epidemiology of polyneuropathy in diabetes and prediabetes. Handb Clin Neurol. 2014;126:3–22.
   PubMedGoogle Scholar
• Papanas N, Ziegler D. New vistas in the diagnosis of diabetic polyneuropathy. Endocrine. 2014;47:690–698.
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–2293.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Panda S, Singh SK. The etiopathogenesis of the diabetic foot: an unrelenting epidemic. Int J Low Extrem Wounds. 2010;9:127–131.
   PubMed Web of Science ®Google Scholar
• Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47:123–128.
   PubMed Web of Science ®Google Scholar
• Daousi C, Benbow SJ, Woodward A, et al. The natural history of chronic painful peripheral neuropathy in a community diabetes population. Diabet Med. 2006;23:1021–1024.
   PubMed Web of Science ®Google Scholar
• Papanas N, Maltezos E. Etiology, pathophysiology and classifications of the diabetic Charcot foot. Diabet Foot Ankle. 2013;4.
   PubMedGoogle Scholar
• Carrington AL, Shaw JE, Van Schie CH, et al. Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period? Diabetes Care. 2002;25:2010–2015.
   PubMed Web of Science ®Google Scholar
• Calles-Escandón J, Lovato LC, Simons-Morton DG, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010;33:721–727.
   PubMed Web of Science ®Google Scholar
• Papanas N, Pafili K, Maltezos E. Charcot osteoarthropathy and coronary artery disease in diabetes: the twilight of innocence? Acta Diabetol. 2016;53:123–124.
   PubMed Web of Science ®Google Scholar
• Van Baal J, Hubbard R, Game F, et al. Mortality associated with acute Charcot foot and neuropathic foot ulceration. Diabetes Care. 2010;33:1086–1089.
   PubMed Web of Science ®Google Scholar
• Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol. 2011;7:682–690.
   PubMed Web of Science ®Google Scholar
• Papanas N, Ziegler D. Corneal confocal microscopy: a new technique for early detection of diabetic neuropathy. Curr Diab Rep. 2013;13:488–499.
   PubMed Web of Science ®Google Scholar
• Papanas N, Ziegler D. Corneal confocal microscopy: recent progress in the evaluation of diabetic neuropathy. J Diabetes Investig. 2015;6:381–389.
   PubMed Web of Science ®Google Scholar
• Papanas N, Boulton AJ, Malik RA, et al. A simple new non-invasive sweat indicator test for the diagnosis of diabetic neuropathy. Diabet Med. 2013;30:525–534.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Papanas N, Roden M, et al. Neuropad: evaluation of three cut-off points of sudomotor dysfunction for early detection of polyneuropathy in recently diagnosed diabetes. Diabet Med. 2011;28:1412–1415.
   PubMed Web of Science ®Google Scholar
• Papanas N, Ziegler D. New diagnostic tests for diabetic distal symmetric polyneuropathy. J Diabetes Complications. 2011;25:44–51.
   PubMed Web of Science ®Google Scholar
• Körei AE, Istenes I, Papanas N, et al. Small-fiber neuropathy: a diabetic microvascular complication of special clinical, diagnostic, and prognostic importance. Angiology. 2016;67:49–57.
   PubMed Web of Science ®Google Scholar
• Callaghan BC, Little AA, Feldman EL, et al. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6:CD007543.
   PubMed Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving -H-H, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591.
   PubMed Web of Science ®Google Scholar
• Sandbæk A, Griffin SJ, Sharp SJ, et al. Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: the ADDITION-Europe Study. Diabetes Care. 2014;37:2015–2023.
   PubMed Web of Science ®Google Scholar
• Charles M, Fleischer J, Witte DR, et al. Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study. Diabetologia. 2013;56:101–108.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Keller J, Maier C, et al. Diabetic neuropathy. Exp Clin Endocrinol Diabetes. 2014;122:406–415.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Fonseca V. From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. J Diabetes Complications. 2015;29:146–156.
   PubMed Web of Science ®Google Scholar
• Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;4:CD007938.
   PubMed Web of Science ®Google Scholar
• Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013;11:CD010567.
   PubMed Web of Science ®Google Scholar
• Zhang -S-S, Wu Z, Zhang L-C, et al. Efficacy and safety of pregabalin for treating painful diabetic peripheral neuropathy: a meta-analysis. Acta Anaesthesiol Scand. 2015;59:147–159.
   PubMed Web of Science ®Google Scholar
• Chaparro LE, Wiffen PJ, Moore RA, et al. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012;7:CD008943.
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”–a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154:2616–2625.
   PubMed Web of Science ®Google Scholar
• Happich M, Schneider E, Boess FG, et al. Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational study. Clin J Pain. 2014;30:875–885.
   PubMed Web of Science ®Google Scholar
• Papanas N, Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014;15:2721–2731.
   PubMed Web of Science ®Google Scholar
• Boulton AJM, Kempler P, Ametov A, et al. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev. 2013;29:327–333.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Behler M, Schroers-Teuber M, et al. Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes. BMJ Open. 2015;5:e006559.
   Web of Science ®Google Scholar
• Várkonyi T, Putz Z, Keresztes K, et al. Current options and perspectives in the treatment of diabetic neuropathy. Curr Pharm Des. 2013;19:4981–5007.
   PubMed Web of Science ®Google Scholar
• Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010;33:1090–1096.
   PubMed Web of Science ®Google Scholar
• Papanas N, Maltezos E. α-Lipoic acid, diabetic neuropathy, and Nathan’s prophecy. Angiology. 2012;63:81–83.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34:2054–2060.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Pritchett YL, Wang F, et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care. 2007;30:664–669.
   PubMed Web of Science ®Google Scholar
• Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014 Jan 3;1:CD007115.
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162–173.
   PubMed Web of Science ®Google Scholar
• Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:328–335.
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;7:CD008242.
   PubMed Web of Science ®Google Scholar
• Hearn L, Derry S, Phillips T, et al. Imipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;5:CD010769.
   Google Scholar
• Hearn L, Moore RA, Derry S, et al. Desipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;9:CD011003.
   Google Scholar
• McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013;8:CD006146.
   PubMed Web of Science ®Google Scholar
• Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162:276–286.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Etropolski MS, Shapiro DY, et al. A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. Clin Drug Investig. 2015;35:95–108.
   PubMed Web of Science ®Google Scholar
• Vadivelu N, Kai A, Maslin B, et al. Tapentadol extended release in the management of peripheral diabetic neuropathic pain. Ther Clin Risk Manag. 2015;11:95–105.
   PubMed Web of Science ®Google Scholar
• Wiffen PJ, Derry S, Moore RA, et al. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;4:CD005451.
   PubMed Web of Science ®Google Scholar
• Zhou M, Chen N, He L, et al. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2013;3:CD007963.
   Google Scholar
• Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysis. Diabetic Med. 2004;21:114–121.
   PubMed Web of Science ®Google Scholar
• McIlduff CE, Rutkove SB. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag. 2011;7:377–385.
   PubMed Web of Science ®Google Scholar
• Mijnhout GS, Kollen BJ, Alkhalaf A, et al. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2012;456279.
   PubMed Web of Science ®Google Scholar
• Çakici N, Fakkel TM, van Neck JW, et al. Systematic review of treatments for diabetic peripheral neuropathy. Diabet Med. 2016 Jan 29. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Garcia-Alcala H, Santos Vichido CI, Islas Macedo S, et al. Treatment with α-lipoic acid over 16 weeks in type 2 diabetic patients with symptomatic polyneuropathy who responded to initial 4-week high-dose loading. J Diabetes Res. 2015;189857.
   Google Scholar
• Ziegler D, Low PA, Freeman R, et al. Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial. J Diabetes Complications. 2016;30:350–356.
   PubMed Web of Science ®Google Scholar
• Kuninaka T, Senga Y, Senga H, et al. Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract. J Cell Physiol. 1991;146:148–155.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Movsesyan L, Mankovsky B, et al. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009;32:1479–1484.
   PubMed Web of Science ®Google Scholar
• Dieckmann A, Kriebel M, Andriambeloson E, et al. Treatment with Actovegin® improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation. Exp Clin Endocrinol Diabetes. 2012;120:132–138.
   PubMed Web of Science ®Google Scholar
• Hammes H-P, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003;9:294–299.
   PubMed Web of Science ®Google Scholar
• Stracke H, Gaus W, Achenbach U, et al. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008;116:600–605.
   PubMed Web of Science ®Google Scholar
• Burness CB, McCormack PL. Capsaicin 8% patch: a review in peripheral neuropathic pain. Drugs. 2016;76:123–134.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain. 2016 Oct 13. pii: S1526-5900(16)30244-9. DOI:10.1016/j.jpain.2016.09.008
   PubMed Web of Science ®Google Scholar
• Snijder R, Ortega E, Perrot S, et al. Capsaicin 8% patch repeat treatment versus standard of care in painful diabetic neuropathy: efficacy of seven consecutive treatments over 52 weeks versus SOC. Diabetologia. 2015;58(Suppl 1):S515(A1069).
   Google Scholar
• Jacobs H, Perrot S, Vinik EJ, et al. Capsaicin 8% patch repeat treatment versus standard of care in painful diabetic neuropathy: safety of seven consecutive treatments over 52 weeks. Diabetologia. 2015;58(Suppl 1):S515(A1070).
   Google Scholar
• Selvarajah D, Wilkinson ID, Emery CJ, et al. Early involvement of the spinal cord in diabetic peripheral neuropathy. Diabetes Care. 2006;29:2664–2669.
   PubMed Web of Science ®Google Scholar
• Selvarajah D, Wilkinson ID, Maxwell M, et al. Magnetic resonance neuroimaging study of brain structural differences in diabetic peripheral neuropathy. Diabetes Care. 2014;37:1681–1688.
   PubMed Web of Science ®Google Scholar
• Argoff CE, Galer BS, Jensen MP, et al. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin. 2004;20(Suppl 2):S21–S28.
   PubMed Web of Science ®Google Scholar
• Wolff RF, Bala MM, Westwood M, et al. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly. 2010;140:297–306.
   PubMed Web of Science ®Google Scholar
• Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14:167–184.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Shapiro DY, Rauschkolb C, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care. 2014;37:2302–2309.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27:151–162.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Etropolski MS, Shapiro DY, et al. A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. Clin Drug Investig. 2015;35:95–108.
   PubMed Web of Science ®Google Scholar
• Rauck RL, Shaibani A, Biton V, et al. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain. 2007;23:150–158.
   PubMed Web of Science ®Google Scholar
• Shaibani A, Fares S, Selam JL, et al. Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain. 2009;10:818–828.
   PubMed Web of Science ®Google Scholar
• Shaibani A, Biton V, Rauck R, et al. Long-term oral lacosamide in painful diabetic neuropathy: a two-year open-label extension trial. Eur J Pain. 2009;13:458–463.
   PubMed Web of Science ®Google Scholar
• Wymer JP, Simpson J, Sen D, et al. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain. 2009;25:376–385.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Hidvégi T, Gurieva I, et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care. 2010;33:839–841.
   PubMed Web of Science ®Google Scholar
• Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;2:CD009318.
   Google Scholar
• Vinik AII, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain. 2007;128:169–179.
   PubMed Web of Science ®Google Scholar
• Jose VM, Bhansali A, Hota D, et al. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet Med. 2007;24:377–383.
   PubMed Web of Science ®Google Scholar
• Rivara M, Zuliani V. Novel sodium channel antagonists in the treatment of neuropathic pain. Expert Opin Investig Drugs. 2016;25:215–226.
   PubMed Web of Science ®Google Scholar
• Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72:1473–1478.
   PubMed Web of Science ®Google Scholar
• Attal N, de Andrade DC, Adam F, et al. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2016;15:555–565.
   PubMed Web of Science ®Google Scholar
• Lakhan SE, Velasco DN, Tepper D. Botulinum toxin-A for painful diabetic neuropathy: a meta-analysis. Pain Med. 2015;16:1773–1780.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Duan WR, An G, et al. A randomized double-blind, placebo- and active-controlled study of T-type calcium channel blocker ABT-639 in diabetic patients with peripheral neuropathic pain. Pain. 2015;156:2013–2020.
   PubMed Web of Science ®Google Scholar
• Campbell CM, Kipnes MS, Stouch BC, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012;153:1815–1823.
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Finnerup NB, Jensen TS. Tailored treatment of peripheral neuropathic pain. Pain. 2012;153:1781–1782.
   PubMed Web of Science ®Google Scholar
• Kiani J, Sajedi F, Nasrollahi SA, et al. A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. J Res Med Sci. 2015;20:359–363.
   PubMed Web of Science ®Google Scholar
• Wallace MS, Marcotte TD, Umlauf A, et al. Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain. 2015;16:616–627.
   PubMed Web of Science ®Google Scholar
• Anand U, Yiangou Y, Sinisi M, et al. Mechanisms underlying clinical efficacy of angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015;11:38.
   PubMed Web of Science ®Google Scholar
• Rice AS, Dworkin RH, McCarthy TD, et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2014;383:1637–1647.
   PubMed Web of Science ®Google Scholar
• Tandon M, Jain S, Balamurugan R, et al. Treatment of pain associated with diabetic peripheral neuropathy with the novel TRPA1 antagonist GRC 17536 in patients with intact peripheral nerve function. Poster presented at NeuPsig; 2015. Neuropathic Pain Congress, 14-17 May 2015, Nice, France.
   Google Scholar
• Vinik A, Rosenstock J, Sharma U, et al. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014;37:3253–3261.
   PubMed Web of Science ®Google Scholar
• Bramson C, Herrmann DN, Carey W, et al. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med. 2015;16:1163–1176.
   PubMed Web of Science ®Google Scholar
• Brown MT, Herrmann DN, Goldstein M, et al. Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. J Neurol Sci. 2014;345:139–147.
   PubMed Web of Science ®Google Scholar
• Wang H, Romano G, Frustaci ME, et al. Fulranumab for treatment of diabetic peripheral neuropathic pain: A randomized controlled trial. Neurology. 2014;83:628–637.
   PubMed Web of Science ®Google Scholar
• Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015;20:658–666.
   PubMed Web of Science ®Google Scholar
• Simovic D, Isner JM, Ropper AH, et al. Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Arch Neurol. 2001;58:761–768.
   PubMed Web of Science ®Google Scholar
• Ropper AH, Gorson KC, Gooch CL, et al. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol. 2009;65:386–393.
   PubMed Web of Science ®Google Scholar
• Ajroud-Driss S, Christiansen M, Allen JA, et al. Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy. Mol Ther. 2013;21:1279–1286.
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Lavery LA, Thethi TK, et al. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. Am J Med. 2013;126:141–149.
   PubMed Web of Science ®Google Scholar
• Wahren J, Foyt H, Daniels M, et al. Long-acting C-peptide and neuropathy in type 1 diabetes: a 12-month clinical trial. Diabetes Care. 2016;39:596–602.
   PubMed Web of Science ®Google Scholar
• Jolivalt CG, Rodriguez M, Wahren J, et al. Efficacy of a long-acting C-peptide analogue against peripheral neuropathy in streptozotocin-diabetic mice. Diabetes Obes Metab. 2015;17:781–788.
   PubMed Web of Science ®Google Scholar
• Bril V, Buchanan RA. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care. 2004;27:2369–2375.
   PubMed Web of Science ®Google Scholar
• Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care. 2006;29:68–72.
   PubMed Web of Science ®Google Scholar
• Bril V, Hirose T, Tomioka S, et al. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care. 2009;32:1256–1260.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Bril V, Kempler P, et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther. 2005;27:1164–1180.
   PubMed Web of Science ®Google Scholar
• Casellini CM, Barlow PM, Rice AL, et al. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care. 2007;30:896–902.
   PubMed Web of Science ®Google Scholar
• Brooks B, Delaney-Robinson C, Molyneaux L, et al. Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin. J Diabetes Complications. 2008;22:88–95.
   PubMed Web of Science ®Google Scholar
• Boyd A, Casselini C, Vinik E, et al. Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate. J Diabetes Sci Technol. 2011;5:714–722.
   PubMedGoogle Scholar
• Bansal D, Badhan Y, Gudala K, et al. Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials. Diabetes Metab J. 2013;37:375–384.
   PubMedGoogle Scholar
• Luvisetto S, Marinelli S, Cobianchi S, et al. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience 2007;145:1–4
   PubMed Web of Science ®Google Scholar
• Bach-Rojecky L, Salković-Petrisić M, Lacković Z Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharmacol 2010;633:10–4
   PubMed Web of Science ®Google Scholar
• Ghasemi M, Ansari M, Basiri K, et al. The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy. J Res Med Sci 2014;19:106–11
   PubMed Web of Science ®Google Scholar
• McCleane G Lacosamide for pain. Expert Opin Investig Drugs 2010;19:1129–34
   PubMed Web of Science ®Google Scholar
• Beyreuther B, Callizot N, Stöhr T. Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol. 2006;539:64–70.
   PubMed Web of Science ®Google Scholar
• Calcutt NA, Jorge MC, Yaksh TL, et al. Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain. 1996;68:293–299.
   PubMed Web of Science ®Google Scholar
• Kastrup J, Angelo H, Petersen P, et al. Treatment of chronic painful diabetic neuropathy with intravenous lidocaine infusion. BMJ. 1986;292:173.
   PubMed Web of Science ®Google Scholar
• Viola V, Newnham HH, Simpson RW. Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. J Diabetes Complications. 2006;20:34–39.
   PubMed Web of Science ®Google Scholar
• White WT, Patel N, Drass M, et al. Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Med. 2003;4:321–330.
   PubMed Web of Science ®Google Scholar
• Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA. 2015;313:2474–2483.
   PubMed Web of Science ®Google Scholar
• Smith MT, Muralidharan A. Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain. Expert Opin Ther Targets. 2015;19:25–35.
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Baastrup C. Angiotensin II: from blood pressure to pain control. Lancet. 2014;383:1613–1614.
   PubMed Web of Science ®Google Scholar
• Su L, Wang C, Yu Y-H, et al. Role of TRPM8 in dorsal root ganglion in nerve injury-induced chronic pain. BMC Neurosci. 2011;12:120.
   PubMed Web of Science ®Google Scholar
• Kahya MC, Nazıroğlu M, Övey İS. Modulation of diabetes-induced oxidative stress, apoptosis, and Ca2+ entry through TRPM2 and TRPV1 channels in dorsal root ganglion and hippocampus of diabetic rats by melatonin and selenium. Mol Neurobiol. 2016 Mar 9. Epub ahead of print.
   PubMedGoogle Scholar
• Facer P, Casula MA, Smith GD, et al. Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol. 2007;7:11.
   PubMed Web of Science ®Google Scholar
• Simpson RW, Wlodarczyk JH. Transdermal buprenorphine relieves neuropathic pain: a randomized, double-blind, parallel-group, placebo-controlled trial in diabetic peripheral neuropathic pain. Diabetes Care. 2016;39:1493–1500.
   PubMed Web of Science ®Google Scholar
• Ogata Y, Nemoto W, Nakagawasai O, et al. Involvement of spinal angiotensin II system in streptozotocin-induced diabetic neuropathic pain in mice. Mol Pharmacol. 2016;90:205–213.
   PubMed Web of Science ®Google Scholar
• Deng X-T, Wu M-Z, Xu N, et al. Activation of ephrinB-EphB receptor signalling in rat spinal cord contributes to maintenance of diabetic neuropathic pain. Eur J Pain. 2016 Jul 27. Epub ahead of print.
   PubMedGoogle Scholar
• Wahren J, Larsson C. C-peptide: new findings and therapeutic possibilities. Diabetes Res Clin Pract. 2015;107:309–319.
   PubMed Web of Science ®Google Scholar
• Hulse RP, Beazley-Long N, Ved N, et al. Vascular endothelial growth factor-A165b prevents diabetic neuropathic pain and sensory neuronal degeneration. Clin Sci (Lond). 2015;129:741–756.
   PubMed Web of Science ®Google Scholar
• Vinik AI. A medicinal food provides food for thought in managing diabetic neuropathy. Am J Med. 2013;126:95–96.
   PubMed Web of Science ®Google Scholar
• Shevalye H, Watcho P, Stavniichuk R, et al. Metanx alleviates multiple manifestations of peripheral neuropathy and increases intraepidermal nerve fiber density in Zucker diabetic fatty rats. Diabetes. 2012;61:2126–2133.
   PubMed Web of Science ®Google Scholar
• Giannoukakis N. Drug evaluation: ranirestat–an aldose reductase inhibitor for the potential treatment of diabetic complications. Curr Opin Investig Drugs. 2006;7:916–923.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Ono Y, Kuromiya A, et al. Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats. Pharmacol Sci. 2008;107:340–348.
   Web of Science ®Google Scholar
• Matsumoto T, Ono Y, Kurono M, et al. Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats. Pharmacol Sci. 2008;107:231–237.
   Web of Science ®Google Scholar
• Ota A, Kakehashi A, Toyoda F, et al. Effects of long-term treatment with ranirestat, a potent aldose reductase inhibitor, on diabetic cataract and neuropathy in spontaneously diabetic torii rats. Diabetes Res. 2013;2013:175901.
   Google Scholar
• Polydefkis M, Arezzo J, Nash M, et al. Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy. J Peripher Nerv Syst. 2015;20:363–371.
   PubMed Web of Science ®Google Scholar
• Giannoukakis N. Evaluation of ranirestat for the treatment of diabetic neuropathy. Expert Opin Drug Metab Toxicol. 2014;10:1051–1059.
   PubMed Web of Science ®Google Scholar
• Danis RP, Sheetz MJ. Ruboxistaurin: PKC-beta inhibition for complications of diabetes. Expert Opin Pharmacother. 2009;10:2913–2925.
   PubMed Web of Science ®Google Scholar
• Vinik A. The protein kinase C-β inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications. Expert Opin Investig Drugs. 2005;14:1547–1559.
   PubMed Web of Science ®Google Scholar
• Javed S, Alam U, Malik RA. Burning through the pain: treatments for diabetic neuropathy. Diabetes Obes Metab. 2015;17:1115–1125.
   PubMed Web of Science ®Google Scholar
• Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes. 1999;48:2090–2095.
   PubMed Web of Science ®Google Scholar
• Cotter MA, Jack AM, Cameron NE. Effects of the protein kinase Cβ inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci (Lond). 2002;103:311–321.
   PubMed Web of Science ®Google Scholar
• Cameron NE, Cotter MA. Effects of protein kinase C beta inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism. Diabetes Metab Res Rev. 2002;18:315–323.
   PubMed Web of Science ®Google Scholar
• Hayase F, Matsuura H, Sanada M, et al. Inhibitory action of protein kinase Cβ inhibitor on tetrodotoxin-resistant Na+ current in small dorsal root ganglion neurons in diabetic rats. Neurosci Lett. 2007;417:90–94.
   PubMed Web of Science ®Google Scholar
• Kharatmal SB, Singh JN, Sharma SS. Calpain inhibitor, MDL 28170 confer electrophysiological, nociceptive and biochemical improvement in diabetic neuropathy. Neuropharmacology. 2015;97:113–121.
   PubMed Web of Science ®Google Scholar
• Paniagua N, Girón R, Goicoechea C, et al. Blockade of sigma 1 receptors alleviates sensory signs of diabetic neuropathy in rats. Eur J Pain. 2016 Jun 24. Epub ahead of print.
   PubMedGoogle Scholar
• Papanas N, Ziegler D. Risk factors and comorbidities in diabetic neuropathy: an update 2015. Rev Diabet Stud. 2015;12:48–62.
   PubMedGoogle Scholar
• Ziegler D, Papanas N, Rathmann W, et al. Evaluation of the Neuropad sudomotor function test as a screening tool for polyneuropathy in the elderly population with diabetes and pre-diabetes: the KORA F4 survey. Diabetes Metab Res Rev. 2012;28:692–697.
   PubMed Web of Science ®Google Scholar
• Tripathi CD, Mehta AK, Yadav AM. Drug combinations in diabetic neuropathic pain: an experimental validation. J Basic Clin Physiol Pharmacol. 2016;27:617–624.
   PubMedGoogle Scholar
• Kharatmal SB, Singh JN, Sharma SS. Voltage-gated sodium channels as therapeutic targets for treatment of painful diabetic neuropathy. Mini Rev Med Chem. 2015;15:1134–1147.
   PubMed Web of Science ®Google Scholar
• Roy MK, Kuriakose AS, Varma SK, et al. A study on comparative efficacy and cost effectiveness of Pregabalin and Duloxetine used in diabetic neuropathic pain. Diabetes Metab Syndr. 2016 Jul 27. Epub ahead of print.
   PubMedGoogle Scholar